Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371617 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01371617: Completed Phase 2 study, sponsored by Infinity Pharmaceuticals.
NCT01371617 is a Phase 2 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01371617, a Phase 2 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with myelofibrosis (MF) (primary myelofibrosis \[PMF\], post-polycythemia vera myelofibrosis \[post-PV MF\], or post-essential thrombocythemia myelofibrosis \[post-ET MF\]).
Interventions
- DRUG IPI-926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01371617 record still lists
NCT01371617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which IPI-926 is the first listed.
NCT01371617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01371617 about?
NCT01371617 is a clinical study titled "A Phase 2 Study With IPI-926 in Patients With Myelofibrosis". The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with myelofibrosis (MF) (primary myelofibrosis \[PMF\], post-polycythemia vera myelofibrosis \[post-PV MF\], or post-essential thrombocythemia myelofibrosis \[post-ET MF\]).
What is the current status of trial NCT01371617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2011-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01371617?
The interventions under investigation include: IPI-926 (DRUG).
Who is sponsoring clinical trial NCT01371617?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01371617's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia